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1 Background  
 
Invasive cervical cancer (ICC), caused by persistent infection with human papillomavirus (HPV), is a 
major public health problem, especially in developing countries[1]. Globally, in 2012 there were 
approximately  528,000 new cases and 266,000 cervical cancer related deaths with over 80% of cases 
occurring in low and middle-income countries (LMIC)[2, 3]. In settings where effective cervical 
screening programs are available, the incidence of cervical cancer has markedly decreased[3, 4]. 
However, in many developing countries, screening programs are not in place or are only available on 
a limited scale, and women frequently present late with the disease leading to high associated 
morbidity and mortality rates.  
Primary prevention for cervical cancer is now possible through vaccination with one of three licensed 
vaccines; the bivalent HPV vaccine (2vHPV) that prevents HPV16 and 18 infection, the quadrivalent 
HPV vaccine (4vHPV) that prevents HPV6/11/16/18 infections and the nonavalent vaccine (9vHPV) 
that prevents HPV6/11/16/18/31/33/45/52/58 infections. These vaccines also have high efficacy 
against persistent infection with HPV vaccine genotypes, a necessary pre-requisite for the 
development of cervical cancer and related cervical lesions[5].  
In 2014, the Strategic Advisory Group of Experts on Immunisation (SAGE) revised recommendations 
for the bivalent and quadrivalent HPV vaccines from a schedule of three doses to two doses at an 
interval of at least 6 months for girls aged 9-14 years old[6] based on evidence of non-inferior 
immunogenicity[7-10]. Recommendations state that girls aged 15 years or older and HIV seropositive 
girls should receive three doses as per original dosage recommendations[6]. 
A recent study collating evidence and lessons learnt from HPV vaccine delivery in LMIC found that 
countries achieved high coverage, especially if they used predominantly school-based delivery 
strategies[11]. By the end of 2016, Gavi, The Vaccine Alliance, had become the primary conduit 
through which LMICs could gain financial support for HPV vaccine introduction and Gavi had 
supported 23 countries to conduct HPV vaccine demonstration programmes. Although an increasing 
number of LMIC have applied for Gavi support and been approved for national scale-up in recent 
years, the sustained financial commitment required for vaccine procurement and delivery is a key 
factor in some governments’ hesitancy to initiate national HPV vaccine programmes[11]. This is 
especially true for countries that are in the process of transitioning out of full financial support from 
Gavi. These countries must increase their co-financing commitments over time until they are 
responsible for purchasing the vaccine at the full Gavi price (currently US$4.50 per dose)[12].  
There is some evidence that a single dose of HPV vaccine may provide protective immune responses 
to prevent incident and persistent HPV infection with vaccine genotypes. A combined, post-hoc 
analysis of 7,466 women aged 18-25 years enrolled in two trials in Costa Rica and the USA who 
received fewer than the recommended number of doses suggested equivalent efficacy of one, two 
and three doses of the bivalent HPV vaccine (2vHPV) against vaccine-type persistent infection over a 
median follow-up of 4 years [13, 14]. Although antibody levels (measured in geometric mean titres) 
four years post-vaccination were lower among girls receiving one dose compared to girls receiving 
either two or three doses, antibody levels were nine-times higher than those elicited by natural 
infection and remained constant up to seven years post-vaccination[15]. In India, 17,729 girls aged 10-
18 years participating in a clinical trial that was suspended because of events unrelated to the study 
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received one, two or three doses of the quadrivalent  HPV vaccine (4vHPV). Single-dose recipients 
elicited lower detectable concentrations of neutralising antibodies to HPV 16 and 18 than two or three 
dose recipients[16]. However, anti-HPV16 and 18 antibody avidity in the one-dose group at 18 months 
was non-inferior to the results after the three-dose regimen at 18 months. The frequency of incident 
HPV 16, 18, 6, and 11 infection was similar irrespective of the number of vaccine doses received, and 
no persistent HPV 16 or 18 infections were detected in any dose group at a median follow-up of 4.7 
years (IQR 4.2–5.1).   
Two observational (non-trial related) studies have evaluated antibody response after one, two and 
three  doses of HPV vaccine, one in Uganda after 2vHPV[17] and one in Fiji after 4vHPV[18].  In both 
studies, girls who were previously vaccinated were recruited and enrolled to determine seropositivity 
and antibody titers to HPV vaccine types. Antibody was determined at three years post-vaccination in 
the Uganda study and at six years post-vaccination in the Fiji study. In both studies, GMTs after one 
dose of HPV vaccine were lower than after two or three doses.  In the Uganda study, GMTs after 
one/two doses of bivalent vaccine did not meet the threshold to be declared non-inferior to three 
doses. However, GMTs of antibody in adolescents who received only one dose in Uganda were still 
higher than women who received one dose of 2vHPV vaccine in the CVT, among whom there were no 
breakthrough cases of disease up to four years after vaccination[15, 19]. In the Fiji study, no significant 
differences in the GMTs across all four HPV types were found between girls who previously received 
two or three doses of 4vHPV. Antibody was detected among one dose recipients six years after 
vaccination, but GMTs were significantly lower than among two- or three-dose recipients. Immune 
memory, as measured by the anamnestic response after a challenge dose of 2vHPV, was evident in all 
one-, two- and three-dose vaccine recipients. 
A recent systematic review of evidence from post-licensure studies of the effectiveness of HPV 
vaccination by the number of doses reported highest effectiveness with three doses but almost half 
of the studies found some evidence of effectiveness with one dose[20]. Of two studies that reported 
vaccine effectiveness for reduction of prevalent vaccine type infection (HPV 16 or 18), one found 
statistically significant effectiveness for three doses but not for two doses or one dose [21]. In the 
second study[22], statistically significant effectiveness was found for three doses, two doses and one 
dose. Neither study performed a formal comparison of effectiveness of three doses vs fewer doses; 
confidence intervals for the effectiveness estimates of three, two and one dose(s) overlapped. Among 
six studies reporting anogenital warts as an outcome, four included a comparison of three, two and 
one doses with no dose; all found highest effectiveness with three doses, and lower but significant 
effectiveness with two doses. Three of the four studies found significant effectiveness with one dose 
[23-27]. Six studies evaluated vaccine effectiveness for prevention of cervical cytological or histological 
abnormalities[28-33]. Outcomes assessed were based on histology only (two), cytology only (two), 
and both cytology and histology (two). Histological abnormalities evaluated included cervical 
intraepithelial neoplasia (CIN) grade 1, 2 and 3 or CIN2+ (CIN grade 2 or worse or adenocarcinoma in 
situ [AIS]) and CIN3/AIS. Among the six studies, all found effectiveness after three doses. Four studies 
found some effectiveness for prevention of high grade histological abnormalities with two doses, and 
two studies found effectiveness with one dose, in some age groups, in analyses with longer buffer 
periods [29, 30]. Most two-dose vaccine recipients received two doses at a one- or two-month 
interval; a longer interval between two doses had no impact on the effectiveness estimate in the one 
study that examined this [30]. No data are currently available on the immunogenicity or efficacy of 
one dose compared to two or three doses of the nonavalent vaccine (9vHPV). 
 
Currently there are several studies underway to investigate efficacy and/or immune responses of a 
single dose HPV vaccine compared to recommended dose regimens. These include the ESCUDDO trial 
in Costa Rica [clinicaltrials.gov registration: NCT03180034][34], the DoRIS trial in Tanzania  
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[clinicaltrials.gov registration: NCT02834637][35] and the HANDS trial in  The Gambia [Research 
Councils UK registration: MC_EX_MR/N006070/1][36]. 
As scientific evidence is being gathered from these trials, it is important to understand the policy 
implications and challenges of changing schedules. In the context of the ongoing single dose vaccine 
trials and  opportunistic analyses of the effectiveness of one dose in HPV vaccine programmes or 
cohorts  with low vaccine schedule completion [17, 18, 20], we approached policy advisors in LMIC for 
their views on the existing evidence for a one dose schedule, analysed the motivators and barriers to 
change existing schedules and what further information would be needed to inform a policy change 
to a one dose schedule in their countries in future.  
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2 Aims and objectives 
We aimed to interview vaccination policy advisors (members of the National Immunization Technical 
Advisory Group [NITAG]) or Expanded Program Immunization [EPI] managers in LMIC to understand 
motivators and barriers to a one dose human papillomavirus (HPV) vaccine schedule.  
The specific objectives were:   
1. To identify key motivators, barriers and information needs for a future, hypothetical, further 
reduction in the HPV vaccine schedule from two doses to one dose, informed by the lessons and 
experience during the transition from three to two doses in LMIC; 
2. To summarize the perceived implications of a further schedule change on the choice of  delivery 
strategy and the perceived cost and sustainability of the programme; 
3. To collate and synthesize attitudes towards any past/current experience of off-label vaccine use 
and the processes needed to implement policy that includes off-label vaccine use.  
3 Methods 
3.1 Country selection 
Low or middle-income countries (as classified by the World Bank) with some experience of HPV 
vaccine delivery through a demonstration programme, pilot or national programme were mapped  
and approached for interview. Due to study timelines, countries were prioritized for interview through 
purposive selection process and were approached in the first instance if they (i) supported a National 
Immunization Technical Advisory Group (NITAG) or equivalent group which critically assesses evidence 
to inform government policy on vaccinations or (ii) had existing links with the study team. The final 
selection of countries included in the study was based on whether the Key Informants (KI) consented 
to be interviewed. 
 
3.2 Interview participants 
Between one and three key stakeholders per country were approached for interview as potential KIs. 
KIs and their contact details were identified through Ministry of Health (MoH) websites and through 
the study investigators’ existing contacts and informal collaborators. KIs considered for inclusion 
comprised (i) members of the NITAG, (ii) Expanded Programme on Immunzation (EPI) managers 
and/or HPV focal points within the EPI programme, or (iii) EPI country partners and/or international 
bodies (e.g. WHO country office, UNICEF). Once the KIs were identified, they were contacted by 
telephone and/or email to enquire about their interest in participating in the study.  
 
3.3 Interview procedures  
A semi structured interview topic guide (Annex 1) was developed to outline the main areas of inquiry 
for the qualitative interviews with policy makers and technical advisors. Key motivators and barriers 
for a one dose HPV vaccine schedule and what information would be needed in any hypothetical 
future discussions around a further schedule change were explored. Interviewees were asked to 
describe the potential implications of a change in schedule on the delivery strategy, perceived cost 
and sustainability of the programme and the possibilities for integration of HPV vaccine into the 
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routine immunisation schedule. Their experience in implementing ‘off-label’ vaccine policy and the 
decision making processes that led to any prior or current ‘off-label’ vaccine use, were explored.  
The first approach to a KI was made via email (Annex 2) and included a one page project summary 
(Annex 3). If no response was received within 7 days, a reminder email was sent or, if contact numbers 
were available, a call was made. Contacts were logged on a contact spreadsheet. If a KI agreed to take 
part in the study, an Informed Consent Form (ICF) (Annex 4) was emailed to the KI for signature, signed 
and returned prior to interview. Interviews were conducted over the telephone or by skype and 
recorded (with written informed consent). If interviewees did not consent to be recorded then the 
notes taken were written up directly after the interview. The interview was conducted with the aid of 
the interview topic guide (Annex 1) and probes used when necessary during the interview. An informal 
interview style was used, including both closed and open-ended questions, in order to gain as much 
information as possible. Interview recordings were either transcribed professionally (n=10), or by staff 
conducting the interview (n=10), or by translators (n=8). Due to difficulties in arranging time for phone 
interview, two interviewees responded to interview questions by email.   
 
3.4 Data management and synthesis 
A standardized data extraction tool was established using Excel 2013 to synthesize the information 
from interview transcripts. Transcribed interviews were entered by the interviewer (NC) and 
independently verified by a second team member (HK). The interview transcripts and recordings were 
on secure servers only accessible by the study team. Qualitative information was synthesized 
according to three themes linked to each of the three objectives (Table 1). Although the anonymity of 
interviewees was maintained for data storage purposes, as per the informed consent procedure, 
participants indicated their consent for their job title and country of interview to be used in reporting 
and other dissemination materials (Annex 4). 
Table 1. Summary of key informant interview questions, by objective 
 Question  
Objective 1:  
Motivators, barriers 
and information needs 
to support a future, 
hypothetical schedule 
change 
What are the perceived advantages of one-dose schedule?  
What are the potential barriers to a one-dose schedule?  
How would a decision on any future schedule change be made and who would be 
involved? 
What information/evidence would be needed for a future schedule change? 
What other factors influence the decision to change schedule?  
Would a one-dose schedule influence the country’s decision to continue/re-
start/pause the HPV vaccine programme? 
Objective 2:  
Perceived implications 
of a further schedule 
change on the choice of  
delivery strategy and 
the perceived cost and 
sustainability of the 
programme 
How might a change to a one-dose schedule influence the recommended delivery 
strategy for HPV vaccine?  
How might a change to a 1-dose schedule influence the integration of HPV vaccine 
into the routine immunisation schedule? or integration with other interventions?  
What might be the implications of a change to a one-dose schedule on the 
affordability and sustainability of the HPV vaccine programme? 
Objective 3:  
Experience with off- 
label vaccine use 
What experience do you know of, in your country, of off-label vaccine use (using a 
vaccine outside of manufacturer recommendations)?  
If there has been experience of off-label use: how was the initial decision made to 
deliver the vaccine outside of manufacturer recommendations? 
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 If there has been no experience of off-label use: how might a decision be made to 
use a vaccine off label (i.e. who would be the key actors involved, stakeholders, 
advisory groups and data needs to inform decision)? 
 
3.5 Ethics 
Ethical approval for this study was granted by the Ethics Committee of the London School of Hygiene 
and Tropical Medicine (no. 9010-1, 2 August 2017).  
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4 Results 
4.1 Description of participating countries and interviewees  
Representatives from 27 LMIC were approached and at least one KI from 18 countries provided 
written consent to be interviewed. Country representation included 9 (50%) countries from the Africa 
region, 5 (28%) from Latin America, 3 (17%) from South East Asia and 1 (6%) European country (Table 
2). At the time of interview, 12 countries were Gavi-eligible (3-year average gross national income per 
capita <1580 USD[12]). One of these (Uganda) had already introduced HPV vaccine nationally and the 
remaining 11 had plans to introduce the vaccine soon (Table 2). Two countries were transitioning 
away from Gavi support (Bolivia and Moldova) and four countries were not eligible for Gavi support 
(Argentina, Brazil, Colombia and Peru).  
Thirty interviews were conducted from August to December 2017. More than one representative was 
interviewed for 11 countries (two interviews were conducted for Kenya, Nigeria, Uganda, Zimbabwe, 
Lao PDR, Nepal, Bolivia, Colombia, Peru and Moldova, and three interviews were conducted for 
Ethiopia; Table 2). A single interview was conducted for the remaining seven countries. Interviews 
were conducted with nine EPI managers, 10 NITAG members, five WHO/national immunization 
managers and six other individuals (an economist/policy advisor in the Department of Policy, Planning, 
and Health Care Financing [Kenya], an immunization programme coordinator [Ethiopia], a coordinator 
of oncological gynecology, National Institute of Cancer in Colombia [Colombia], two WHO country 
Vaccine Officers [Nepal], a former Minister of Health [Peru]). The KI (a NITAG member) from one 
country in sub-Saharan Africa requested that the country remain anonymous (Country Z). 
Table 2.  Summary of the participating countries, HPV vaccine experience and key informants 
Region Country Gavi 
eligibility 
status 
National Programme 
Status1  
HPV vaccine 
experience 
        Stakeholders interviewed 
Africa Ethiopia Eligible  Soon to introduce (Gavi 
application successful, 
projected introduction 
2018) 
 
Gavi demo 
2015-17 
1. WHO Routine Immunization Officer  
2. National Immunisation Programme 
Officer 
3. National Immunisation programme 
Coordinator   
Kenya  Eligible  Soon to introduce  
(Gavi application 
sucessful, projected 
introduction 2019) 
GAP demo 
2011;  
Gavi demo 
2013-17 
1. Economist/ Policy Advisor for the 
Department of Policy, Planning, and 
Health Care Financing 
2. National Immunization Programme 
Officer  
Lesotho  Eligible  Introduced 2012-16 
(paused) 
GAP demo(s) 
2009-2011; 
National 2012-
2016 
1. WHO Immunization Officer for Lesotho  
Country ‘Z’ Eligible  Unknown Gavi demo 
2014-15 
1. NITAG Member  
Nigeria Eligible  Unknown None 1. NITAG member  
2. NITAG member 
Senegal Eligible Soon to introduce (Gavi 
application successful, 
projected introduction 
2018) 
Gavi demo 
2015-17 
1. EPI manager, coordinator of national 
immunization programme 
Uganda Eligible  
  
Introduced 2015 Demo(s) 2008-
14 
Natl. 2015- 
1.       EPI Team Leader  
2.       EPI HPV Focal Person 
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Region Country Gavi 
eligibility 
status 
National Programme 
Status1  
HPV vaccine 
experience 
        Stakeholders interviewed 
 
Zambia  Eligible  Soon to introduce (Gavi 
application sucessful; 
projected introduction 
2019) 
GAP demo 
2013-14 
1.       National EPI Manager  
Zimbabwe Eligible  Soon to introduce (Gavi 
application successful, 
projected introduction 
2018) 
Gavi demo 
2015-17 
1. Director of Epidemiology and Disease 
Control and Zimbabwe NITAG 
Chairperson 
2. EPI Manager    
South East 
Asia 
Lao PDR Eligible  Soon to introduce (Gavi 
application sucessful; 
projected introduction 
2019) 
Gavi demo 
2013-15 
 
1. National immunisation Programme 
Manager 
2. NITAG member 
Nepal Eligible  Unknown Demo 2008-
2015 
 
1. Technical advisor to NITAG  
2. Vaccine Officer for WHO Nepal Office 
Solomon 
Islands  
Eligible  Soon to introduce (Gavi 
application successful; 
projected introduction 
2019) 
Gavi demos 
2015-17 
1. EPI Programme Officer 
Latin 
America 
Argentina Ineligible Introduced 2011 Natl2: 2011- 
 
1. Director of Preventable Diseases (MoH) 
Bolivia Accelerated 
transition 
phase3 
Introduced 2017 Demos 2009-
2011 
Natl.: 2017- 
1. PAHO/WHO Bolivia EPI Consultant 
2. President of NITAG 
Brazil Ineligible Introduced 2014 Demos 2010-
12 
Natl. 2014- 
 
1. Coordinator of National Immunization 
Program at MoH, NITAG member 
Colombia  Ineligible Introduced 2012 Natl. 2012- 1.      NITAG and  EPI National   Coordinator  
2.      Other 
Peru Ineligible Introduced 2011 Demos 2007-
2010 
Natl. 2011- 
1. Former Minister of Health; Dean of the 
Public Health Faculty at the Cayetano 
Heredia in Peru 
2. NITAG President  
Eastern 
Europe 
Moldova Fully self-
financing 
 
Unknown Gap Demo 
2010-11 
1.      Head of Epidemiology Department of   
preventable diseases through 
vaccination within the National Centre 
for Public Health and NITAG member 
2.       NITAG Secretary  
1The status of the country’s plans for national Introduction of HPV vaccine was informed by investigator’s previous contact with the 
country representatives and Gavi’s forcasting of successful applications. ‘Soon to introduce’ meant an application for HPV vaccine support 
had been prepared  by country representatives (and may have been submitted for Gavi’s consideration or a date for submission was 
planned).  
2National programme was modified in 2017 to include delivery to boys and catch up vaccination to 26 years of age for people living with 
HIV. 
3Gavi support was provided for the first year of the national programme only. 
 
4.2 Perceived advantages of a 1 dose HPV vaccine schedule 
Of the 30 KIs interviewed, 27 KIs (90%) representing all 18 countries thought that a future, 
hypothetical schedule change to a single dose HPV vaccine schedule would be supported by key 
stakeholders within their country. Three KIs did not respond to the question directly. KIs cited the 
following potential advantages of a single dose HPV vaccine schedule: a reduction in programme costs, 
operational or logistical advantages (such as easier implementation of one dose in schools including 
less interruption of school activities, fewer visits and ease of integration into routine immunisation 
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services/ other outreach activities), high vaccine coverage (uptake of the first dose was reported to 
be high in previous HPV vaccine programmes but some countries had experienced lower second dose 
coverage, which had reduced the overall reportable coverage), easier integration with other services 
(e.g. annual child health days), reduced cold chain storage requirements, potentially increased 
community acceptability (due to fewer visits and injections) and a potential to expand vaccination to 
other groups (such as boys or older women [Brazil]), given the reduced cost of a one dose schedule 
(Table 3).  
Table 3.  Perceived advantages of a single dose HPV vaccine schedule 
Perceived advantages of a 1-dose schedule  KIs  
N=301 
Countries  
N=18 
Reduction in costs  15 11 
Operational/logistical advantages1 15 12 
High coverage 7 7 
Easy integration into routine immunisation 4 3 
Lower cold chain requirement 3 2 
Increased community acceptability  3 3 
Potential to extend vaccination to other groups 1 1 
Did not respond 3 3 
1KIs cited more than one advantage; 1Operational or logistical advantages refers to easier implementation of one dose in schools including 
less interruption of school activities, fewer visits and ease of integration into routine immunisation services.  
The KI from the Solomon Islands reported that a schedule reduction could be well received by 
communities because parents would no longer have to keep track of how many doses their daughters 
had been given and that health care workers (HCW) would also find vaccine delivery logistically 
simpler: 
“[A one dose schedule] will be less work for nurses. The current schedule takes time, takes a 
lot of their energy. If they have one dose schedule then they go to schools and it’s less time 
vaccinating just one cohort of girls….  so they have more time doing other activities in the 
clinics….We have a high problem with logistics and transportation in the country. A one dose 
schedule would have a good advantage for the nurses in the clinics.” KI, Solomon Islands 
4.3 Perceived barriers to a 1 dose HPV vaccine schedule  
KIs from the same country were not always in agreement in their perception of potential barriers to 
the introduction of a single dose schedule. Fourteen KIs from 13 countries (Argentina, Bolivia, Brazil, 
Lao PDR, Lesotho, Moldova, Country Z, Nepal, Nigeria, Solomon Islands, Uganda, Zimbabwe and Peru) 
did not anticipate any barriers to the hypothetical introduction of a one dose HPV vaccine schedule in 
their country.  
Eight other KIs from 6 countries (Ethiopia, Kenya, Lao PDR, Senegal, Zambia and Zimbabwe) cited 
concerns around gaining community or individual acceptance of a single dose schedule in place of 
two/three doses as a potential barrier to a one dose HPV programme. KIs referred to the potential for 
individuals or communities to question whether one dose is sufficient to provide adequate protection, 
given the mobilisation and communication to date on the importance of receiving two or three doses 
(Table 4). In Kenya, there was concern that a further schedule change to one dose rapidly after the 
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schedule was reduced from three to two doses, could be perceived by communities as a lack of 
sufficient evidence on which schedule is effective:  
"It does raise concerns of very fast changes. i.e. it implies that comprehensive research was 
not really done at the outset and we are more on a trial and error phase which many are not 
comfortable with." KI, Kenya. 
Seven KIs from six countries (Colombia, Ethiopia, Kenya, Uganda, Zambia and Zimbabwe) cited 
potential acceptability  issues among HCWs as a potential barrier to a one dose HPV vaccine 
programme, given that their training to date has specified two/three doses. In Uganda, there were 
challenges with HCW when the HPV vaccine schedule was reduced fromthree to two doses. Although 
training was conducted, information was received at different times and the change in practice among 
HCWs after training was not immediate, so whilst some health workers in the country were 
administering two doses, others were still giving three doses. The KI recommended that a clear 
communication strategy would be needed to ensure that both HCWs and communities understood 
the recommendations around a further schedule reduction to assure them that one dose would 
provide effective protection.  
In Peru, the KI explained that a formal recommendation from the WHO would be advantageous to 
support the dose change and would be useful to dispel any resistance propagated by anti-vaccine 
groups. KIs from three countries mentioned the potential for information around a further schedule 
change to be used negatively by girls who have been affected by adverse events following 
immunisation, anti-vaccine groups or the media (Colombia, Peru, Kenya): 
“I think [a one dose schedule] could be very good for the ones who are not vaccinated yet, 
but could be a ‘battle horse’ for the ones who are saying that they suffered adverse effects 
from the vaccine, because they could use a further schedule reduction to say “you gave us 
more doses than we needed and that is why we got ill”.” KI, Colombia 
“I always fear the anti-vaccine groups. For example, if in some years ahead someone who 
received only one dose developed cancer” KI, Peru 
Other health systems disadvantages were also cited. One Ethiopian KI mentioned that a single visit 
would impact the frequency of contact between the HCW and the adolescent, thereby decreasing the 
opportunity for the provision of sexual and reproductive health (SRH) services for adolescents. Five 
KIs stated that sourcing the resources needed for the retraining of HCWs and remobilisation of the 
community would be a challenge if no extra support was provided (Kenya, Ethiopia, Bolivia, Uganda, 
Country Z). Other perceived financial implications of a reduction to a one dose schedule are collated 
in Section 4.6. 
Table 4. Perceived barriers to 1 dose HPV vaccine schedule 
Perceived barriers to 1 dose HPV vaccine schedule KIs N=301 Countries N=18 
No barriers perceived 14 13 
Community or individual acceptance1 8 6 
Acceptability among healthcare workers  6 6 
Negative media or anti-vaccine groups 3 3 
Cost of re-mobilisation/ retraining necessary 5 5 
14 
 
Did not respond 2 2 
1KIs cited more than one barrier. 1 Community or individual acceptance refers to communities questioning whether one-dose is sufficient/ 
mis-trust.  
4.4 Decision making body and evidence needed for change to vaccine programme 
The decision-making body, processes and evidence needed for a future HPV vaccine schedule change 
described by KIs are summarised in Tables 5, 6, 7, 8. 
KIs from all but three countries (Lesotho, Nepal and the Solomon Islands) reported that their countries 
had a NITAG in place, although some NITAGs had been recently established and so had still limited 
functionality. Countries used a variety of different governmental departments to research and review 
available vaccine-related information and to make decisions on vaccine introduction or changes to 
current vaccination programmes within their country Tables 5, 6, 7, 8.  
All KIs from all 18 countries stated that at least one source of information would be required as part 
of the decision-making process around a future, hypothetical HPV vaccine schedule change (some 
KIs cited multiple sources). KIs from nine countries (Ethiopia, Senegal, Uganda, Laos, Nepal, Solomon 
Islands, Bolivia, Peru and Kenya) thought that a WHO position paper or a WHO recommendation 
would be required before policy makers would consider a change to a one dose HPV schedule. KIs 
from eight countries (Lesotho, Country Z, Senegal, Uganda, Argentina, Brazil, Peru and Zambia ) 
stated that evidence on the efficacy of one dose of HPV vaccine against HPV infection and/or clinical 
endpoints to compared to two or three doses, would be important in the decision-making process 
around a change in schedule. KIs from 10 countries (Lesotho, Country Z, Nigeria, Senegal, Nepal, 
Argentina, Bolivia, Brazil, Colombia and Moldova) said that evidence on the immunogenicity of one 
dose of HPV vaccine compared to two or three doses would be important for the decision-making 
process. Countries are classified into groups based on the highest level of evidence perceived to be 
required for a change of HPV vaccine schedule in Table 9. Only KIs from Argentina stated explicitly 
that policy makers would not necessarily need to wait for formal WHO recommendations to enact a 
change in vaccination policy (e.g. schedule or dosage), unless it was an issue with significant 
controversy. 
Other data considered important for policy makers to consider if deliberating over a change to a one 
dose HPV vaccine schedule were evidence on durability of protection (KIs from Country Z, 
Zimbabwe, Laos, Nepal, Bolivia and Colombia); cost-effectiveness data on a single dose HPV vaccine 
programme (2 KIs: Country Z and Peru) and ‘untold experiences’ (i.e. experiences from other 
researchers or implementers of one dose programmes) by one KI from Nigeria.  
The Nepal WHO officer stated that there might be interest in Nepal to help generate data on the 
immunogenicity and effectiveness of a single dose of HPV vaccine. 
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Table 5. Summary of decision making body, decision-making process and reported evidence needs in countries from the African region, as reported by 
KIs 
Country Decision making 
body 
NITAG  
(Yes/No)  
Decision-making process for vaccine policy Reported evidence needed for any 
consultation on a further change to the HPV 
vaccine schedule 
Ethiopia The Inter-Agency 
Coordinating 
Committee (ICC) makes 
the final decision on all 
national vaccination 
programmes, (vaccine 
introductions and 
delivery strategies) 
Yes The NITAG deliberates over new vaccine introductions and drives 
discussion around changing vaccine schedules. The ICC receives advice 
from the NITAG to inform a decision. ICC Meetings are held every 2 
weeks involving working groups, technical advisors and national 
immunisation coordinators. When new evidence is available it is 
reviewed at these fortnightly meetings and formal requests to the 
NITAG are issued for their recommendation.  The ICC also discuss the 
evidence available with partners globally, regionally and nationally, 
including groups from the professional healthcare society. 
- WHO recommendations 
- Data from demonstration projects/ national 
programmes from other countries 
implementing one dose 
- Data on non-inferior immune response of one 
dose compared to two or three doses  
 
Kenya MoH working group 
including other 
stakeholders e.g. 
Ministry of Education 
(MoE), WHO and 
UNICEF, other MoH 
departments 
(reproductive health, 
health promotion and 
cancer programme).   
 
Yes A proposed change to a programme is presented to the NITAG and a 
recommendation from the NITAG is requested. The NITAG will form a 
working group, who will develop a policy recommendation. The 
working group present this recommendation to the NITAG and they 
will come up with the final recommendation. Finally the 
recommendation is presented back to the cabinet secretary and the 
MoH.  
- WHO recommendations 
- Due to lack of in-country data, data from 
other countries on efficacy of one dose would 
be useful especially in the context of HIV 
given the high prevalence.  
Lesotho   No but the 
country is in the 
process of 
forming one 
(early stage 
development) 
Currently, decisions are made by the EPI and the MoH with involvement 
from the Reproductive Health Programme and Department of Disease 
Control. When the country made the decision to change from 3 to 2 
doses, the recommendations from WHO were submitted to the MoH 
and the dose schedule was changed. 
- Data demonstrating non-inferiority of 
immune responses (evidence from other 
countries would be considered when no 
national level data is available)   
Nigeria MoH working group 
including professors in 
community health/ 
public health, infectious 
diseases, pathology, 
and gynaecologists. 
Yes (formed in 
2015)  
The NITAG meets quarterly.  The NITAG is composed of individuals from 
a broad range of backgrounds. Recommendations pass to the MoH. The 
National Primary Healthcare Development Agency within the MOH is in 
charge of implementation of vaccines and all of the operational 
aspects. 
- Information on costs  
- ‘Untold experiences’ from researchers who 
have implemented one dose vaccine  
- Immunogenicity data from other countries, 
especially similar African countries   
- Evidence from peer reviewed journals on 
one dose safety/ duration of protection  
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Country Decision making 
body 
NITAG  
(Yes/No)  
Decision-making process for vaccine policy Reported evidence needed for any 
consultation on a further change to the HPV 
vaccine schedule 
Senegal The Comités de 
Coordination Inter-
Agences (CCIA) or 
Interagency 
Coordination 
Committees (ICC)  
Yes The CCIA would follow the WHO guidelines and consider all available 
evidence as provided in the WHO guidelines with advice from the 
NITAG. The CCIA would also consider the potential benefits of dose 
reduction, e.g. reduction in resources needed for 1 dose 
administration, finance and avoiding drop-out/loss-to-follow-up for 
further doses. Senegal has a broad involvement from the MoH, MoE, 
Ministry of Finance and civil society representatives and international 
partners.  
 
- WHO position paper  
- Evidence of one dose non-inferiority vs.  
two/three doses (immunogenicity and 
efficacy against infection) 
Uganda MoH and the Supporting 
Immunization and 
Vaccination Advisory 
Committee (SIVAC) 
Yes NITAG consults and evidence is presented and discussed. This is then 
presented to the MoH and the Supporting Immunization and 
Vaccination Advisory Committee (SIVAC) who make the final decision.  
- WHO recommendations 
- Evidence of non-inferiority of immune 
responses and efficacy against infection and 
clinical endpoints.  
 
  
Zimbabwe MoH, MoE, the 
communicable and non-
communicable disease 
units, the Child Health 
team. 
Yes During the process of dose reduction from 3 to 2 dose HPV vaccine, the 
NITAG, MoH, MoE, the communicable and non-communicable disease 
units reviewed the evidence and recommendations. For the HPV 
vaccine, they needed to go beyond the traditional EPI approach, 
because the age group was well outside the under 5 year old target age 
group. Different stakeholder groups were needed to review evidence 
and give advice on implementation/ vaccine delivery.  A strategic 
advisory group was formed specifically for decisions concerning the 
HPV vaccine. The Permanent Secretary of the MoH is the chair of this 
new group.  
- Non-inferiority of 1 dose in terms of duration 
of protection (i.e. would girls need a booster 
at some point if they were only getting one 
dose?) with in-country/ regional data on 
effectiveness.  
 
Country ‘Z’ The Research Institute 
of National Health. 
Yes NITAG review evidence with Research Institute of National Health. Then 
recommendations are made to MoH who have final decision. 
- Immunogenicity of one dose, and evidence of 
duration of protection;  
- Research on financial impact, including cost-
effectiveness analysis 
 
 
 
 
17 
 
Table 6. Summary of decision making body, decision making process and evidence used in countries from South East Asian region  
Country Decision making 
body 
NITAG 
(Yes/No) 
Decision making process Evidence needed for consultation  
Laos PDR National Immunisation 
Committee (NIC) 
including members 
from the MoH, 
Ministry of Science, 
Ministry of Planning 
and Investment and 
MoE 
Yes The NITAG reviews all the evidence available and invite scientists to 
present and reviews the evidence with them. The NITAG make 
recommendations after this review and present it to the NIC. The NIC is 
led by the MoH. The decision makers (the NIC) aim to balance the 
investment and benefit to the country and so once they review the 
recommendations of NITAG the NIC make a decision. 
- WHO position paper (Concrete evidence from 
the WHO that one dose achieves the same 
level of immunogenicity as 2 doses) 
- Research from other countries including 
African countries, European regions, America, 
Australia including data on the incidence and 
prevalence of cancer in the country.  
- Evidence on duration of protection would 
also be important.  
Nepal National Committee 
for Immunization 
Practice (NCIP) 
represented by 
various government 
and independent 
experts 
No Various factors govern the decision-making including cost, 
sustainability, overall safety, and effectiveness of vaccine. Whenever an 
application to Gavi for any new vaccine introduction is made, the 
application needs to be endorsed by the Inter Agency Coordination 
Committee (ICC), Ministry of Finance, and the Ministry of Health.  
 
- WHO position paper  
- Established evidence showing the non-
inferiority of 1 dose in terms of immune 
response and effectiveness including the 
long-term protection (regional and country 
level data is required).  
Solomon Islands EPI technical working 
group, Director of 
Reproductive Health, 
ICC, MoH  
No The decision-making process starts with the EPI technical working 
group which forms a committee chaired by the Director of 
Reproductive Health.  This committee reviews evidence, presenting any 
advantages and disadvantages of a new policy/ a policy change and 
then makes a recommendation to the ICC and MoH who make the final 
decision. The final decision is therefore based on the information 
provided by the EPI technical working group. 
 
- WHO recommendations,  
- Evidence of non-inferiority of one dose (in 
terms of immune responses or against 
infection endpoints) from other countries.   
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Table 7. Summary of decision making body, decision making process and evidence used in countries from South American region  
Country Decision making body NITAG  Decision making process Evidence needed for consultation  
Argentina The MoH department of Disease 
Control and Prevention 
Yes - Internal plan at MoH level showing the need of the new vaccine strategy 
(e.g. reduction to one dose)  
- An internal evaluation of the programmatic (logistic) aspects including an 
evaluation of human resource requirements   
- Once the decision is taken around logistic/ programmatic feasibility, the 
NITAG evaluates the evidence  
- The NITAG makes the scientific recommendation 
- The scientific recommendation is evaluated at the MoH  level, and the 
decision is taken. 
- Non-inferiority of 1 vs. 2 doses in terms 
of immunogenicity and efficacy against 
cervical disease from international 
research as well as from national and 
local data (surveillance data available 
from a national register of cervical 
lesions and cervical cancer) 
 
Bolivia The MoH, the Pan-American 
Health Organization (PAHO), 
WHO and The Immunization 
National Program. 
Yes The NITAG will analyse all the information and will present a report and a 
suggestion to the MoH.  
- WHO/ PAHO position paper  
- Recommendations from the vaccine 
manufacturer  
- Evidence showing that 1 dose HPV 
vaccine has a non-inferior immune 
response compared to 2/3 doses (i.e. 
that antibody titres are equivalent and 
durable)  
- A formal recommendation from the TAG 
(Consultant Technical Group) 
Brazil Technical Committee of 
Immunisation: paediatricians, 
immunologists, gynaecologists, 
and immunization coordinators 
(state and municipal level). 
Yes The Committee meets twice a year to evaluate evidence and define the 
immunisation policy around the country. This group is advisory, providing 
recommendations to MoH. The MoH works together with other directors from 
the Ministry of Health to decide on recommendations using the scientific 
evidence and economical sustainability. 
- Data on immunogenicity, safety, 
international evidence on infection and 
clinical outcomes (there are not enough 
national studies in relation to the 
vaccines) 
Colombia the  Ministry of Health and Social 
Welfare make final decision.  
Yes The NITAG includes representatives from National Academic of Medicine, 
Paediatricians organization and Immunology organizations. They make 
recommendations and the MoH, who also consults the Colombian Federation of 
Obstetrics and Gynaecology, the Colombian Society of Paediatrics, the Colombian 
Federation of Perinatology, the National Institute of Health and the National 
Institute of Oncology, and PAHO. The MOH then needs to comply with the 
recommendations.  
- Non-inferior immunogenicity (or 
immunobridging studies) and efficacy of 
1 dose compared to 2 doses and 
duration of protection  
- Lessons from other countries that 
introduce a single dose  
 
Peru MoH Yes The Minister of Health invites experts in the NITAG to review evidence on issues 
(NITAG or PAHO can also intiate an evidence review at NITAG). The expert 
committee discuss it. If necessary they would bring more experts and finally vote 
on the decision. Usually the decision is unanimous. The Minister of Health 
ratifies policy for the change.  
- WHO position paper 
- Cost-effectiveness data; 
- International or national data showing 
that the efficacy with one dose at least 
the same level demonstrated by two 
doses 
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Table 8. Summary of decision-making body, decision making process and evidence used in countries from East European region  
Country Decision making 
body 
NITAG 
(Yes/No) 
Decision making process Evidence needed for consultation  
Moldova MoH Yes The NITAG and WHO give recommendations to the MoH who makes 
the final decision. 
 
- The immunogenicity of one dose would 
be sufficient evidence 
 
 
Table 9. Countries classified by the highest level of evidence that KIs perceived may be needed for any future discussions on a further reduction of the 
HPV vaccine schedule  
 Reported evidence needed for consideration of a dose reduction 
Countries Immunogenicity data  Efficacy data against a clinical endpoint (+/- 
immunogencity data) 
WHO position paper  
(+/- immunogencity and efficacy data) 
 Nigeria 
Colombia  
Moldova 
Lesotho  
Country Z 
Argentina  
Brazil  
Zambia 
Zimbabwe 
Ethiopia 
Senegal  
Uganda 
Laos 
Nepal 
Solomon Islands  
Bolivia 
Peru 
Kenya 
Total  3 6 9 
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4.5 Perceived implications of schedule change on HPV vaccine delivery strategy 
KIs from all 18 countries discussed the perceived implications of a schedule change on vaccine delivery 
strategy. As background, the main strategies used for HPV vaccine delivery, in pilots or national 
programmes, as reported by KIs were school-based, school-based with community outreach for out 
of school girls and health facility-based strategies with/without community outreach (Table 10). 
Health facility-based delivery with/without community outreach represented the delivery strategy 
most integrated with existing routine health facility activities whereas school-based strategies 
generally represented a campaign style delivery approach.  
Table 10. HPV vaccine delivery experience and perceived implications of a further schedule change 
to the vaccine delivery strategy  
Country HPV 
vaccine 
experience  
National Programme 
Status 
Delivery strategy experience  KI perspective on delivery strategy for 1 
dose schedule  
Ethiopia Gavi demo 
2015-17 
Soon to introduce (Gavi 
application successful, 
projected introduction 
2018) 
Demo exp: School based + 
community outreach 
Natl. plans: School based  
No change 
Kenya  GAP demo 
2011; Gavi 
demo 
2013-17 
Soon to introduce  
(Gavi application 
sucessful, projected 
introduction 2019) 
Natl. plans: School based No change but would propose to 
integrate with another service 
delivered in schools such as deworming 
or health education on hygiene i.e the 
school health days or malezi bora 
campaigns 
Lesotho  GAP 
demo(s) 
2009-2011; 
National 
2012- 
Introduced Natl. exp: School-based  Integrate into routine immunisations 
services at the health facility with 
outreach 
Country ‘Z’ Gavi demo 
2014-15 
Unknown Demo exp: School + health 
centre based + outreach 
Uncertain; potentially integrated with 
annual vitamin A campaigns 
Nigeria None Unknown N/A Uncertain  
Senegal Gavi demo 
2015-17 
Soon to introduce (Gavi 
application successful, 
projected introduction 
2018) 
Demo exp/ Natl. plans: 
School + health centre based 
+ outreach 
No change 
Uganda Demo(s) 
2008-14 
Natl. 2015- 
Introduced Natl. exp: health facility 
based + outreach 
No change  
Zambia  GAP demo 
2013-14 
Soon to introduce (Gavi 
application sucessful; 
projected introduction 
2019) 
Demo exp: Schools + health 
facilities 
Potentially integrate into Child Health 
Week campaign, which includes 
deworming and immunisation 
Zimbabwe Gavi demo 
2015-17 
Soon to introduce (Gavi 
application successful, 
projected introduction 
2018) 
Demo exp: School + health 
centre based + outreach. 
Natl. plans: School + health 
facility 
No change 
Lao PDR Gavi demo 
2013-15 
Soon to introduce (Gavi 
application sucessful; 
projected introduction 
2019) 
Demo exp: School + health 
centre based + outreach. 
Unknown 
Nepal Demo 
2008-2015 
Unknown Demo exp: School + health 
centre based 
No change 
Solomon 
Islands  
Gavi demos 
2015-17 
Soon to introduce (Gavi 
application successful; 
projected introduction 
2019) 
Demo exp: School + health 
centre based + outreach. 
No change; easier to integrate with TT 
and Oral Polio vaccine outreach 
delivered by the chool health 
programme 
Argentina Natl: 2011- Introduced Natl. exp: school + Health 
facility + outreach 
(dependent on province) 
No change; currently integration of 
Hepatitis B, rubella, meningitis and first 
dose of HPV  
Bolivia Demos 
2009-2011 
Natl.: 2017- 
Introduced School based No change; possibly integrate with 
tetanus  
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Brazil Demos 
2010-12 
Natl. 2014- 
Introduced Natl. exp: school + Health 
facility 
No change. Integrated with Meningitis 
C and diphtheria vaccine 
Colombia  Natl. 2012- Introduced  Health centres No change  
Peru Demos 
2007-2010 
Natl. 2011- 
Introduced Natl. Exp: School based No change  
Moldova Gap Demo 
2010-11 
Unknown Demo. Exp: School-based  Uncertain  
Information collated from KIs and Gavi application documents at gavi.org 
The majority of KIs stated that a change in schedule would not alter the recommended delivery 
strategy for HPV vaccine in their country (Table 10). KIs from just two countries (Country Z and Zambia) 
mentioned that a single dose strategy may be easier to integrate with existing annual health day 
campaigns rather than delivery through their routine existing health system activities and therefore a 
change of delivery strategy may be considered.  
KIs from 6 countries (Nigeria, Kenya, Ethiopia, Lesotho, Country Z, Zambia) felt that integration of HPV 
vaccine delivery with other services could be easier with a single dose schedule e.g. if combining 
vaccination with annual health days or other annual vaccine campaigns. Delivery of HPV vaccine 
together with other services was perceived to be more cost-effective than delivering HPV vaccine 
alone.  
KIs from Bolivia mentioned that a further dose reduction could present the opportunity for vaccinating 
a wider cohort such as a wider age group or another target group, or that the money saved could 
potentially also go to another vaccine programme. 
 
4.6 Implications of a 1 dose HPV vaccine schedule on affordability of vaccine 
supply and delivery 
In total, 22 KIs from 15 countries offered their perspectives on the implications of a change in schedule 
on the cost and sustainability of the HPV vaccine programme. The KIs from the same country were all 
in agreement on this point. Four KIs from 3 countries (Senegal, Solomon Islands, Uganda) were unsure 
as to what extent the reduction of schedule would affect the cost of the HPV vaccination programme, 
stating that the cost would depend on the cost of the single dose formulations and the delivery 
strategy used. The remaining 18 KIs from 12 countries (Argentina, Bolivia, Brazil, Ethiopia, Kenya, Lao, 
Lesotho, Moldova, Country Z, Nepal, Zambia, Zimbabwe) perceived that a reduction in schedule would 
reduce the overall cost of vaccine procurement and delivery. KIs from 2 countries (Bolivia, Brazil) 
mentioned that the cost-savings of a reduction in HPV vaccine schedule could be used to invest in 
other interventions . Lesotho mentioned that a reduction in schedule and concomitant reduction in 
programme cost could help re-start the national HPV vaccination programme.  
“The country is preparing to start the vaccine again after it stopped. There is a strong need to 
reintroduce the vaccine now, so a one dose schedule would be more than appreciated.” KI 
Lesotho 
The KI from Moldova stressed that despite a potential reduction in cost, political will would need to 
increase for the HPV vaccine to be successfully introduced nationally: 
“There is not sufficient political support at this moment… it took us a lot of effort to convince 
them [the government] to do the pilot. The key to the decision to introduce will be deeply 
rooted in the financial aspects. Currently the National Immunization Program is entirely 
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covered from the State budget and HPV vaccine is the most expensive one out of the whole 
spectrum of vaccines proposed for funding by the Immunization Program” KI Moldova 
As stated in the barriers section, KIs from five countries (Kenya, Ethiopia, Bolivia, Uganda, Country Z) 
said that it may be a challenge to source the additional resources needed for social mobilisation and 
HCW retraining on a change in schedule.  
Despite recognising that a reduced schedule could potentially substantially reduce the cost of the HPV 
vaccine programme, KIs from 7 countries (Ethiopia, Lao, Country Z, Nepal, Solomon Islands, Uganda, 
Zimbabwe) mentioned residual concerns over the sustainability of their HPV vaccine programme.  
“It is already hard to sustain the vaccines that we have in our programme, introducing a new 
one is increasing the burden that we already have.  But of course, if you’re going for the one 
dose approach it would be much, much easier to manage.” KI Country Z 
Two KIs (Ethiopia, Zimbabwe) specifically stated that for the programmes to be sustainable, the cost 
of the vaccine still needs to reduce, despite a one dose schedule and Gavi support. 
“[One dose] will help in the shorter-term… HPV will only be sustained longer-term if the price 
of that 1 dose is negotiated again” KI Ethiopia  
 “The price of the vaccine still needs to be reduced even with a reduction to one dose.” KI 
Zimbabwe 
Among the 12 countries eligible for Gavi support, the restricted time period in which the country will 
benefit from Gavi support for HPV vaccine was mentioned by 8 KIs in 6 countries (Ethiopia, Lao PDR, 
Country Z, Nepal, Solomon Islands, Zimbabwe) as a contributing factor to their assessment of the 
implications of a one dose schedule on cost and sustainability of the HPV programme.  
“Current national rollout support from Gavi ends in 2021. The country is going to take on board 
[the cost of] not just HPV vaccine, but other vaccines as well. It is now in the level of the 
executives. They are aware of our transition, that we are graduating soon from Gavi, so they 
are working out whether other support will come once we have graduated from Gavi.” KI 
Solomon Islands 
KIs from Kenya and Uganda specifically stated that a single dose programme could alleviate costs and 
resources associated with tracing and catch-up of girls who miss their second/third dose. 
In two countries (Bolivia and Brazil) the provision of specific vaccines is enshrined by law, once a 
vaccine is included in the national immunisation programme, the government guarantees its 
availability. KIs reported they would therefore be able to spend the savings from a reduced HPV 
vaccine schedule on vaccinating a wider cohort of girls or older women or reallocate fnds to introduce 
a different vaccine.  
 
4.7 Experience with off-label vaccine use 
KIs from nine of the 18 countries interviewed knew of no prior experience of off-label vaccinations in 
their country (Ethiopia, Kenya, Country Z, Nigeria, Senegal, Uganda, Zimbabwe, Lao PDR and 
Moldova), and felt that the country would need to have WHO recommendations in place to proceed 
with any future off-label use. KIs from four (24%) countries  reported that policy makers were currently 
considering off-label vaccination: the delivery of fractional doses of inactivated polio vaccine (IPV; 
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Lesotho, Zambia, Nepal and the Solomon Islands), and an out of cold chain (OCC) project for Hepatitis 
B vaccine was also reported by the Solomon Islands (Table 11). KIs from all five of the Latin American 
countries interviewed reported that the country had previous experience of using vaccines off-label 
or outside current recommendations (Argentina, Bolivia, Brazil, Colombia, Peru, Table 11). This 
included off-label experiences with Hepatitis A, polio and pertussis vaccines.  
Table 11. Summary of experience of past or current ‘off-label’ vaccine use in the national 
immunisation programmes of nine countries 
Country Past/current  Reported experience 
Africa region    
Lesotho ‘under 
consideration’ 
Fractional dosage of IPV  
Zambia ‘under 
consideration’ 
Fractional dosage of IPV 
South East Asia/Oceania  
Nepal ‘under 
consideration’ 
Fractional dosage of IPV 
Solomon Islands Current An out of cold chain project for Hepatitis B vaccine  
Fractional dose IPV also ‘under consideration’ 
Latin American region  
Argentina Past - Reduction in Hepatitis A vaccine schedule from two to one dose  
- Reduction in pneumococcal conjugate vaccine schedule from four to 
three doses 
- Reduction in varicella vaccine schedule from two to one dose 
- Administration of pertussis vaccine to pregnant women 
Bolivia Past Prolonged storage and use of multi-dose vials of IPV beyond manufacturers 
recommendations 
Brazil Past Reduction in Hepatitis A vaccine schedule from two to one dose  
Colombia Past Pertussis vaccine in pregnant women and fractional dose IPV  
Peru Past Early adoption of pneumococcal conjugate vaccine reduced schedule of three 
doses (the ‘2+1’ schedule) 
 
Case studies of off-label vaccine use 
The KI from Argentina reported several experiences of off-label use, outside of manufacturer 
recommendations. These included (i) administration of a pertussis vaccine in pregnant women, off-
label but within WHO recommendations; (ii) Reduction in Hepatitis A vaccine (HAV) schedule from 
two doses to one dose, off-label and outside of recommendations; (iii) early adoption of a reduced 
schedule of pneumococcal conjugate vaccine in children in a schedule of three doses (two primary 
doses and a booster dose) rather than four doses, off label but within WHO recommendations; (iv) 
one dose varicella vaccine rather than two doses, off-label and outside of WHO recommendations. 
The decision to change the Hepatitis A vaccine schedule from two doses at 12 and 18 months of age, 
to one dose was made in the context of budget constraints due to flooding around the country, an 
outbreak of Hepatitis A and limited supply of HAV in 2005. Policy makers decided to prioritise high 
coverage with a single dose, nationwide in unvaccinated children, rather than implement a low 
coverage programme of two doses, to prevent another outbreak. At this time, there was a committee 
in place which was smaller than the NITAG and an expert group who made the recommendation to 
reduce the schedule with participation from representatives from the provinces. The epidemiological 
surveillance group synthesised and evaluated the evidence on one dose HAV schedule and, once a one 
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dose programme was initiated, conducted surveillance every five years to evaluate the need for a 
second dose.  
In Bolivia, the reported experience of off-label use of the inactivated polio vaccine (IPV) in 2014-15 
was in the context of a global shortage of available vaccine. The KI reported that the country 
considered two options: (i) extending the use of multi-dose vials beyond manufacturer 
recommendations to reduce wastage, and (ii) using a fractional dose (1/5th of the full IPV dose) 
administered intradermally. Manufacturer recommendations stated that the multi-dose vial should 
be discarded within 8 hours of first puncture but, by the time the vaccine was introduced in Bolivia in 
2015, the WHO had devised recommendations to allow the vial to be used for up to 28 days after first 
puncture under certain storage conditions. These recommendations were informed by well-designed 
studies that indicated the vaccine was stable for 28 days following first puncture. Regional meetings 
of NITAG and MOH representatives, coordinated by Pan-American Health Organization (PAHO), were 
organised across the Latin American continent. The Bolivian NITAG generated a formal 
recommendation to the MoH that supported the extended use of the multi-dose vaccine vials to 
reduce wastage and extend the supply of the vaccine. The MoH subsequently organised training and 
information to prepare for the change and this to be implemented. The MOH reportedly encountered 
no challenges when making the decision, given the  evidence from well-designed studies that indicated 
that the vaccine was stable for 28 days. However, there was some resistance from health professionals 
who queried why national recommendations and those on the label differed. 
In Brazil, a single dose schedule of hepatitis A vaccine is used rather than the recommended 2 dose 
schedule. The NITAG initiated the recommendation during a period of low vaccine stock following  
evidence from published studies that a single dose is approximately 80% effective. The immunisation 
program at the MoH took the recommendation to the Minister of Health for the final decision. The 
MoH then informed the media. There were no barriers to the off-label use of HAV as the community 
and civil society recognised the importance of the vaccine and the constraints on supply.  
In Colombia, the KI reported that the HPV vaccine programme initially started with a schedule of 3 
doses (0, 2 and 6 months) but this changed quickly to a 0/6/60 months schedule as there was some 
evidence showing that the 3rd dose was not necessary. Two KIs reported that the government in 
Colombia had been considering the dose reduction before the dose change was approved by the WHO 
or at the national level by the NITAG. Colombia also has used the pertussis vaccine (Tdap) among 
pregnant women without a strong recommendation from PAHO. In 2012 and 2013, there were some 
outbreaks of pertussis and pregnant women were vaccinated following evidence from different 
studies and a recommendation from the NITAG. There were few barriers when implementing these 
changes. Efforts were made to communicate with the scientific community, and specifically with 
doctors, paediatricians and gynaecologists.  Training was organised and guidelines published, and the 
changes were well accepted by the medical community and the community in general. Due to low 
stocks of the polio vaccine, Colombia is currently preparing for fractionated IPV use. Approximately 
11,000 health workers have been trained in the intradermal delivery, using 1/5 of the recommended 
dose.  
Countries with no experience of off-label use 
The Zimbabwe KI explained that introduction of new vaccines or changes to vaccines have to go 
through the Zimbabwe Medicines Control Authority. The MoH works closely with the regulators who 
must be notified if there is a change to a formulation or dose and to conduct quality assurance.  This 
can be a lengthy process so, if there was to be a dose reduction, the MoH and the regulators would 
need advanced warning so that the introduction of a one dose vaccine would not be delayed. The only 
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way to waiver the full registration process with the Medicines Control Authority would be in an 
emergency such as an outbreak. The vaccine would still have to be re-registered but the MoH could 
begin implementation whilst the registration process was on-going.  
Lao PDR has no experience in using vaccines off-label. The KI suggested that healthcare workers like 
nurses would be very reluctant not to follow manufacturer or WHO recommendations. The IPV 
vaccine shortage is used as an example. Despite the fact that the WHO suggested fractional dosing, 
this was not implemented in Lao PDR to avoid confusion among healthcare workers.  
 
A summary of study findings is presented in Table 11 with more detailed summary of information 
from KI interviews in Supplementary Table 1. 
Table 12. Summary of some key findings  
 
Date of 
national 
HPV 
vaccine 
intro’ 
Readiness and perceived advantages Barriers Information needs 
Country Would 
support 
1-dose 
NITAG in 
place 
Experience of 
off-label 
vaccine use 
Community 
mobilisation 
needed1  
HCW 
mobilisation 
needed2 
Concerns 
over 
negative 
media 
WHO 
recommendation 
required 
Other 
country 
lessons on 
1-dose 
Ethiopia 2018* Yes Yes No Yes Yes  Yes Yes 
Kenya  2019* Yes Yes No Yes Yes Yes Yes  
Lesotho  2012-16 Yes None (in 
development) 
Under 
consideration 
   
 
 
Country Z  NA Yes Yes 
 
   
 
 
Nigeria NA Yes Yes No    
 
 
Senegal 2018* Yes Yes No Yes   Yes  
Uganda 2015- Yes Yes No  Yes  Yes  
Zambia  2019* Yes Yes Under 
consideration 
Yes Yes  
 
 
Zimbabwe 2018* Yes Yes No3 Yes Yes  
 
 
Lao PDR 2019* Yes Yes No3 Yes   Yes Yes  
Nepal NA Yes Yes Under 
consideration 
   Yes  
Solomon 
Islands  
2019* Yes None Yes (current)    Yes  
Argentina 2011- Yes Yes Yes (past)    No4  
Bolivia 2017- Yes Yes Yes (past)    Yes5  
Brazil 2014- Yes Yes Yes (past)    
 
 
Colombia  2012- Yes Yes Yes (past)  Yes Yes 
 
Yes 
Peru 2011- Yes Yes Yes (past)   Yes Yes  
Moldova NA Yes Yes No    
 
 
1Concerns were raised over community acceptance of (another) schedule change/ mistrust/ the additional resources needed to re-mobilise the 
community 
2Concerns over health care worker acceptance of a new schedule and the additional resources needed for re-training.   
3KIs indicated any approval for off-label use would take a long time to be processed and/or would not be considered 
4KIs in Argentina were the only KIs to indicate that WHO recommendation would not necessarily be needed prior to introduction of a change in 
HPV schedule (other KIs either explicitly stated they would be needed or did not mention them) 
5Bolivian KIs also mentioned manufacturer recommendations for the schedule change may be needed.  
*Projected introduction date based on Gavi application; NA: unknown/ not available 
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5 Discussion  
 
Key immunisation stakeholders from 27 countries were approached for interview on the potential 
implications of a future, hypothetical further reduction of the HPV vaccine schedule from two to one 
doses. Thirty KIs from 18 countries (67%) provided written consent to be interviewed. 
Overall, the KIs interviewed in this study suggested there would be support for a hypothetical future 
simplification of the HPV vaccine schedule to a single dose. It was generally acknowledged that this 
would reduce the resources required for delivery, the discomfort and inconvenience to the 
vaccinees and the financial commitment required for vaccine procurement. A number of KIs stressed 
that, although a single dose schedule might alleviate some of the logistical and financial challenges 
of HPV vaccine delivery, there remained a need for strong political will, social mobilisation and 
healthcare worker training to ensure programme success and longevity. Some KIs also called for 
continued efforts to reduce the vaccine per-dose cost, citing residual concerns over HPV vaccine 
programme sustainability. 
The decision-making processes and information needs for a future hypothetical one dose schedule 
change were fairly similar across countries. NITAGs were perceived to play an important role in 
independently assessing evidence and providing a recommendation to the decision-makers. WHO 
recommendations on vaccine introduction and delivery also play a key role, especially in Africa, in 
decisions to introduce or change vaccine programmes. WHO recommendations were reported as 
being used to reassure communities about a change in vaccine policy should negative media or 
rumours arise. KIs from half of the countries interviewed stated that they felt a WHO 
recommendation for a single dose schedule would be needed prior to a schedule change in their 
country. KIs from three of the 18 countries specifically stated that they would want to hear lessons 
from other countries that had introduced a single dose schedule, i.e. that they would not want to be 
the first to implement. There were concerns that the change in policy could fuel negative media 
coverage of the national immunisation programme.  Only KIs from Argentina stated explicitly that 
policy makers would not necessarily need to wait for formal WHO recommendations to enact a 
change in HPV vaccination policy, but that they may wait if the change was likely to be a 
controversial issue. 
Known prior experience of off-label vaccine use was concentrated in the South American countries 
that were interviewed. Here, schedule reductions for Hepatitis A, varicella and pneumococcal 
conjugate vaccines were introduced nationally without/prior to WHO recommendations. There may 
be other examples of off-label vaccine use  that were not reported by the KIs. 
There were a number of study limitations. We were not able to collect information from nine of the 
27 countries approached for interview and the interviews conducted represented the individual 
opinion of the KIs rather than a consensus reached by those making vaccination policy. There may be 
different conclusions drawn if the outlined decision-making processes in the country were followed 
e.g. on the information needed prior to a schedule reduction or the implications of a schedule change 
on the recommended delivery strategy. 
Randomised controlled trials are underway to analyse whether 1-dose delivers non-inferior 
immunogenicity and efficacy to 2 and 3 dose regimens. In conclusion, we found wide ranging 
support among 27 vaccine policy makers and advisors from 18 LMICs for a future further reduction 
in the HPV vaccine schedule to a single dose if there were immunological data and/or clinical 
evidence of efficacy to support this change. 
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Supplementary Table 1. Summary of key factors involved in decision on HPV dose reduction (from 2/3 to 1 dose) 
Country Key decision makers + 
summary of decision making 
Potential support 
for 1 dose by policy 
makers? 
Evidence necessary to 
make change 
Factors that may 
influence decision  
Perceived advantages 
for one dose 
Barriers to dose 
reduction 
Experience of off-label 
use?  
Benin NITAG will review evidence 
(immunogenicity and efficacy 
against HPV/clinical 
endpoints) from peer 
reviewed publications and 
WHO papers and consult with 
MoH and MoF.  
Not a NITAG 
member or WHO 
EPI representative 
so did not want to 
respond 
Data on immunogenicity 
among young girls 
demonstrating that 1 dose 
is not inferior to 2-doses 
Availability of trial 
data showing non-
inferiority of 
immune response 
Easily integrated into 
routine immunisation 
services  
None cited, but notes 
that acceptability 
among HCW and 
community would need 
to be addressed 
Did not want to respond to 
this question 
Ethiopia Evidence and information is 
reviewed by the NITAG who 
make a recommendations to 
the ICC (Inter-Agency 
Coordinating Committee). 
The ICC make the final 
decision.  
Yes – provided 
there is adequate 
evidence that one 
dose is effective 
against cervical 
cancer and cost 
effective 
WHO position paper; 
Discussion with partners 
globally, regionally, 
nationally, including 
groups from the 
professional healthcare 
society; evidence gathered 
from different countries as 
well as other journals or 
articles 
WHO position 
paper; Regulator 
has put WHO pre-
qualification as one 
of the requirements 
to register the 
vaccine to enter 
into the country, as 
well as WHO 
endorsement 
There will be 
logistical/programmatic 
advantages as it will be 
easier to deliver (in one 
visit) and would improve 
coverage; integration 
with other programmes 
(adolescent sexual 
health programme) 
Acceptance by HCW or 
the community that 1 
dose is as effective as 
2/3 doses. One dose 
schedule reduces time 
HCW spends with child 
(less opportunity to 
advocate on sexual 
health). Public might 
query the frequency of 
dose change (3 ->2 ->1) 
No off label example given 
but decisions around this 
topic would be made by the 
ICC. The NITAG 
recommendation would 
have an influence on any 
decision made. They would 
want to align in country 
recommendations with 
WHO recommendations 
with the manufacturer 
recommendations. 
Kenya  TAG follow recommendations 
by WHO. DATA & literature is 
reviewed and MoH make final 
decision. 
Yes- if community 
accepts it. More 
affordable  
The review from 3 to 2 
then 1 dose in such a short 
time span makes KI 
sceptical as believes it 
shows lack of thorough 
evidence collection on 
which schedule is actually 
effective before 
recommending to 
countries. 
  More affordable  Community acceptance 
–when changing from 3 
to 2 doses 
communities felt their 
girls were getting less 
protection and there 
was negative media 
coverage for HPV.  
No experience given  
Lesotho No NITAG (in development). 
EPI and MoH; involvement 
from members of 
Reproductive Health 
Programme and Department 
of Disease Control. No 
requirement for WHO 
recommendation.  
Yes  Data from other countries 
demonstrating non-
inferiority 
Social mobilisation 
activity 
1 dose vaccine will be 
more easily integrated 
into routine 
immunisation services 
at health facilities. It will 
be more cost-effective 
No barriers (provided 
there is a good 
communication 
strategy in place) 
No experience but currently 
considering using fractional 
doses of IPV due to stock 
shortages 
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Country Key decision makers + 
summary of decision making 
Potential support 
for 1 dose by policy 
makers? 
Evidence necessary to 
make change 
Factors that may 
influence decision  
Perceived advantages 
for one dose 
Barriers to dose 
reduction 
Experience of off-label 
use?  
Liberia  MoH, MoE and Ministry of 
Gender and Development; IIC 
(Independent Information 
Commission) and Technical 
Advisory Group (TAG). The 
EPI, ICC and TAG review the 
evidence together at 
meetings and form a decision 
on the best course of action 
to take. 
Yes  WHO position paper, 
Evidence that one dose is 
non-inferior to 2/3 doses; 
evidence on durability of 
infection (will 1 dose be 
sufficient protection for 
life?) 
No response It would likely increase 
coverage compared to 
multi-dose vaccine 
Acceptability by the 
community. Good 
communication 
strategy required, 
targeting community 
leaders, parents and 
girls (there is a low 
level of understanding 
around the HPV 
vaccine and distrust 
within the 
communities around 
healthcare 
programmes) 
No experience 
Country Z NITAG review evidence with 
Research Institute of National 
Health. Then 
recommendations are made 
to MoH who have final 
decision. 
Yes- it would have a 
big economic 
impact on 
acquisition and 
implementation of 
the vaccine.  
Immunogenicity of 1 dose, 
Will these girls be 
protected in 30 years 
(duration of protection). 
Research on financial 
impact, is the cost 
reduction worth reducing 
the dose? 
  Economic impact on 
acquisition and 
implementation of the 
vaccine. 
Does not think there 
would be any barriers. 
Some community 
acceptance issues 
perhaps.  
No, Discussions on the 
Polio vaccine but no 
recommendations made for 
off label use.  
Nigeria  NITAG advises the MoH on 
what that new new should be 
introduced 
Yes- more feasible 
and acceptable 
 ‘untold experiences’ from 
other researchers with 
respect to one dose 
compared to 2/3 dose. For 
immunogenicity data, they 
would consider data from 
other countries, especially 
African countries 
Duration of protection  
     None perceived  No experience 
Senegal NITAG, Comités de 
Coordination Inter-Agences 
(CCIA) ; MoH, MoE, Ministry 
of Finance and civil society 
representatives and 
international partners. 
Recommendations are made 
by the NITAG. The CCIA take 
on board these 
recommendations and review 
Yes WHO position paper ; 
Evidence that one dose is 
non-inferior to 2/3 doses 
Resources to 
mobilise and to 
inform the people 
about the change in 
policy 
Reduction in resources 
and finance needed; 
avoidance of drop-out 
or loss to follow up of 
girls.  
No barriers perceived, 
provided there is a 
good communication 
strategy in place to 
address potential 
issues of acceptability 
by HCW and 
community 
No experience 
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Country Key decision makers + 
summary of decision making 
Potential support 
for 1 dose by policy 
makers? 
Evidence necessary to 
make change 
Factors that may 
influence decision  
Perceived advantages 
for one dose 
Barriers to dose 
reduction 
Experience of off-label 
use?  
all the evidence before 
making the final decision.   
The Gambia  NITAG still in its early stages. 
Decision for HPV involves the 
cervical cancer technical 
working group (consisting of 
Immunisation programme, 
Hospitals, gynaecologists, The 
Medical Council, Civil Society, 
Department of Reproductive 
Health and Child 
Development). This working 
group examine evidence and 
make recommendations to 
the ICC and the MoH who 
make the final decision.   
Yes- The most at 
risk group are out of 
school girls, a 1 
dose would make it 
easier to make sure 
out of school girls 
were covered. And 
it would reduce cost 
slightly.  
Non-inferiority of immune 
responses of 1 dose vs. 2/3 
dose 
  Reaching out of school 
girls.  
KI was confident that 
there would not be any 
barriers. Health care 
workers would 
welcome a 1 dose and 
community would 
accept 1 dose. 
No experience of off label 
use. They have completed a 
study on how they would 
introduce a fractional dose 
of IPV as campaign set up 
due to stock shortages but 
this has not been 
introduced. Decision 
process for off label use 
would involve the NITAG 
who would make 
recommendations to the 
ICC and MoH. If it was 
regarding a 1 dose schedule 
for HPV the cervical cancer 
technical working group 
would also be involved in 
reviewing evidence with 
the NITAG. 
Uganda NITAG; The MOH contacts the 
NITAG for advice and the 
NITAG will come up with a 
recommendation after 
reviewing evidence.  
Yes WHO position paper; 
evidence on effectiveness 
of one dose compared 
with 2 doses of the HPV 
vaccine.  
Resources to 
mobilise and to 
inform the people 
about the change in 
policy 
Only one visit required – 
perhaps higher coverage 
will be achieved 
Acceptability by HCW 
or the community 
No experience 
Zambia  NITAG review with technical 
working groups and MoH 
then final decision made by 
the ICC 
Yes  Would like in country data 
as well as data from other 
countries of clinical 
efficacy and 
immunogenicity  
  Could potentially 
combine it with bi-
annual health week.  
Minimal barriers if 
there is adequate 
social mobilisation to 
ensure community 
acceptance.  
They gave 2 doses of HPV 
before the manufactures 
had changed the 
label.Currently considering 
fractional dose of IPV. 
Zimbabwe NITAG, MoH, MoE, 
Department of 
Communicable and Non-
communicable disease units; 
Child Health team. Evidence 
is reviewed by the above and 
the MoH make the final 
decision.  
Yes – provided 
there is adequate 
evidence that one 
dose is as effective 
as 2/3 doses 
Evidence that one dose 
would still protect girls at 
given (recommended) age 
and duration of protection 
Interviewee 
suggested that 
evidence on efficacy 
of 1 dose in older 
women (in their 
early 20s) would be 
considered 
important (linked to 
There will be 
logistical/programmatic 
advantages as it will be 
easier to deliver (in one 
visit)  
Acceptance by HCW or 
the community that 1 
dose is as effective as 
2/3 doses 
Any new vaccines or 
changes to vaccine 
administration must be 
reviewed by the Zimbabwe 
Medicines Control 
Authority. The MoH works 
closely with the regulators 
who must be notified if 
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Country Key decision makers + 
summary of decision making 
Potential support 
for 1 dose by policy 
makers? 
Evidence necessary to 
make change 
Factors that may 
influence decision  
Perceived advantages 
for one dose 
Barriers to dose 
reduction 
Experience of off-label 
use?  
age of first 
marriage) – would 
they need a booster 
later?  
there is a change to 
formulation or dose and 
conduct quality assurance. 
The only way to waiver the 
full registration process 
with the Medicines Control 
Authority would be in an 
emergency such as an 
outbreak 
Lao PDR NITAG, National 
Immunisation Committee 
(NIC) made up of: MoH, 
Ministry of Science, Ministry 
of Planning and Investment, 
Ministry of Education; 
UNICEF. Evidence is reviewed 
by the NITAG with scientists. 
They then report to the 
National Immunisation 
Committee (NIC) who analyse 
everything.  Once they review 
the recommendations of 
NITAG the NIC make a 
decision about the vaccine. 
Yes - provided there 
is sufficient 
evidence 
demonstrating non-
inferiority of 1 dose, 
it would be 
accepted by policy 
makers as it would 
be easier for 
implementation. 
WHO position papers; 
research from other 
countries; Evidence on 
duration of protection 
No response There will be 
logistical/programmatic 
advantages as it will be 
easier to deliver 
Acceptance by HCW or 
the community. Public 
might query the 
frequency of dose 
change (3 ->2 ->1), 
especially if a 
neighbouring country 
may still be using 2-
doses. Good 
communication 
strategy required 
No experience 
Nepal The NITAG called the National 
Committee for Immunization 
Practice (NCIP); represented 
by various government and 
independent experts 
 Yes  WHO position paper; long 
term protection would 
need to show non 
inferiority to the 2 -dose or 
3- dose schedule.  
Regional and country level 
data if available 
  Easier to implement, 
cheaper and would 
require less cold chain 
storage 
 None perceived from 
district or field level 
but there may be 
questions on the 
change at the policy 
level, county level, 
committee level and 
Ministry level – WHO 
position paper would 
be needed 
 Fractional dose of IPV 
Solomon 
Islands 
No NITAG. EPI technical 
working group where the 
director of reproductive 
health chairs the committee; 
recommendation to the MoH 
executive, permanent 
secretary for the MoH is the 
Yes- It would be 
very convenient. 
Teams will go to the 
schools once a year, 
if the evidence 
shows it has an 
impact and it works 
WHO recommendations, 
the impact of the one 
dose, what works well in 
schedules in other 
countries, what would be 
the advantage of one dose 
in our setting (data from 
No response other 
than information 
they would require. 
Logistically easier, time 
saving for healthcare 
professionals delivering 
the vaccine, more 
sustainable in the long 
term. 
No barriers if 
sensitization 
programme is well 
implemented to make 
sure it is accepted by 
the communities.  
started an out of cold chain 
(OCC) project for hep B 
vaccine but currently still 
using the monovalent that 
is currently used in the 
country we haven’t gone as 
far as to use Controlled 
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Country Key decision makers + 
summary of decision making 
Potential support 
for 1 dose by policy 
makers? 
Evidence necessary to 
make change 
Factors that may 
influence decision  
Perceived advantages 
for one dose 
Barriers to dose 
reduction 
Experience of off-label 
use?  
chairperson- they make final 
decision.  
and approved 
through the right 
channel.  
other countries that have 
trialled one dose). 
Temperature Chain (CTC) 
where we can use the off 
label vaccine 
Argentina  NITAG, or CONAIN [Comisión 
Nacional de Inmunizaciones] 
is an independent 
commission; including 
representatives of scientific 
societies, a Provincial 
Representative who 
represent the 4 regions of the 
country, and a representative 
from PAHO. CONAIN makes 
the recommendations but 
final decisions are taken by 
the MoH. 
 Yes  the non-inferiority of 1 
dose vs. 2 dose in terms of 
immunogenicity and 
efficacy against cervical 
disease from international 
research as well as from 
national and local data 
   Fewer doses would 
guarantee a higher 
coverage, decrease in 
financial cost and 
feasibility/programmatic 
efforts. 
 
 None perceived 
 
 Various experiences: 
including reduced dose of 
Hepatitis A vaccine – 
decision made through 
NITAG (CONAIN) 
 
Bolivia NITAG, PAHO, WHO, the 
Immunization National 
Program. The NITAG check 
the evidence presented from 
studies,  trials, WHO 
recommendations and formal 
recommendations from The 
Immunization National 
Program, Pan America Health 
Organization (PAHO), SAGE 
(Strategic Advisory Group of 
Experts) and WHO. The 
NITAG and OPS then generate 
formal recommendations to 
the Health Ministry.  
Yes - provided that 
studies generate 
evidence 
demonstrating one 
dose would provide 
the same immunity 
over time as two 
doses of the 
vaccine.  -  It would 
likely be supported 
from an economic 
perspective, and 
because of the 
operational and 
logistical 
advantages to 
delivery  
WHO position paper, 
manufacture 
recommendations; 
(prospective) evidence 
showing that 1 dose HPV 
vaccine has a non-inferior 
immune response 
compared to 2/3 doses; 
formal recommendation 
from the TAG (Consultant 
Technical Group) is 
required from PAHO and 
the SAGE (Strategic 
Advisory Group of Experts) 
from WHO, together with 
the trial evidence 
demonstrating non-
inferiority of clinical 
endpoints 
Time to the 
availability of the 
trial data on the 
duration of 
immunity.   
Economic and 
operational advantages, 
easier to implement and 
reduces cost.  
Acceptability by HCW 
or the community who 
are familiar with 2-
dose (addressing 
concerns that 1 dose is 
as effective as 2/3 
doses) 
Experience with using the 
polio vaccine off-label in 
2014 due to shortage of 
available vaccine – the 
solution was to extend the 
use of opened vials beyond 
manufacturer 
recommendations. 
Regional Latin American 
meetings were organised 
by PAHO, and involved the 
NITAG and MoH. Evidence 
was presented from studies 
demonstrating stability of 
the vaccine up to 28 days 
(beyond manufacturer 
recommendations). There 
was no resistance from the 
authorities in the countries. 
However, there were some 
challenges encountered 
with HCW.When 
considering the use of HPV 
vaccine off-label, there 
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Country Key decision makers + 
summary of decision making 
Potential support 
for 1 dose by policy 
makers? 
Evidence necessary to 
make change 
Factors that may 
influence decision  
Perceived advantages 
for one dose 
Barriers to dose 
reduction 
Experience of off-label 
use?  
would need to be evidence 
demonstrating that 1- dose 
would have the same 
immunity over time as the 
two dose schedule.  This 
evidence on 1 dose should 
be made available (in 
addition to WHO 
endorsement) for 
presentation at the annual 
regional meeting   
Brazil  The Technical Committee of 
Immunisation includes 
paediatricians, 
immunologists, 
gynaecologists, and 
coordinators of immunization 
at the state and municipal 
level. The Committee meets 
twice a year to evaluate 
evidence and define the 
immunisation policy around 
the country. 
 Yes  immunogenicity, safety, 
international evidence on 
infection and clinical 
outcomes (there are not 
enough; The Committee 
also verifies whether 
changes that are have 
been already 
recommended by others 
regulatory agencies and 
other countries have been 
made and any 
recommendations from 
PAHO are considered 
   Higher coverage would 
be obtained; allow 
opportunity to extend 
the vaccination program 
(older women >15 yrs). 
 None perceived but 
training of HCW  will be 
required and social 
campaigns needed to 
inform public 
 
 Various experiences: 
including reduced dose of 
Hepatitis A vaccine (due to 
low quantities available); 
decision through NITAG 
Colombia  NITAG review and make 
recommendations with 
Colombian Federation of 
Obstetrics and Gynaecology, 
the Colombian Society of 
Paediatrics, the Colombian 
Federation of Perinatology, 
the National Institute of 
Health and the National 
Institute of Oncology, and 
PAHO  then the  Ministry of 
Health and Social Welfare 
make final decision.  
Yes- it is more 
affordable  
Scientific data on 
immunogenicity. Strong 
evidence one dose will be 
as effective as 2-doses in 
protecting girls in 30 years 
(duration of protection).  
  Easier to implement, 
could incorporate into a 
routine immunisation 
programme.  For e.g., 
they have an annual 
health week where they 
give children 
immunisations and 
vitamins. It could be 
incorporated into this 
perhaps.   
Community 
acceptance- there is a 
lot of mistrust in the 
vaccine due to . claims 
of side effects. 
Participation in schools 
dropped considerably 
so delivery strategy 
was switched to health 
centre. Would need a 
lot of help to get the 
public back on board 
with HPV. 
Yes- whooping cough 
vaccine in pregnant 
women, and fractionated 
polio intradermic vaccine 
(due to low stock) 
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Country Key decision makers + 
summary of decision making 
Potential support 
for 1 dose by policy 
makers? 
Evidence necessary to 
make change 
Factors that may 
influence decision  
Perceived advantages 
for one dose 
Barriers to dose 
reduction 
Experience of off-label 
use?  
Peru   NITAG includes an expert 
committee from MoH, from 
different societies (like the 
paediatrician’s society), 
academic sector and PAHO – 
the change is discussed and if 
necessary they would bring 
more experts and vote on the 
decision. Once approved, the 
policy change is 
implemented.  
 Yes provided there 
is evidence 
demonstrating non-
inferiority 
WHO position 
paper;  efficacy of two 
doses), plus the analysis 
done by the Office of 
Health Technology 
Assessment, which 
includes the cost/benefits 
evidence. We would need 
the [international or 
national] data showing 
that the effectivity with 
one dose would be at least 
the same level showed by 
two doses.  
   Increased 
uptake/coverage 
 Community 
acceptance and anti-
vaccine groups 
 MMR vaccine [measles, 
rubella and mumps]:  2 
doses at 12/18 months. The 
recommendation is 2 doses 
at 12/48 months;  
anti-pneumococci vaccine 
in children:  3 doses 2+1: 
means 1st dose at 2 
months, 2nd dose at 4 
months and 3rd dose at 12 
months 
Moldova  NITAG make 
recommendations to MoH. 
MoH take on board 
recommendations from 
NITAG and WHO and make 
final decision  
Yes- reduces cost 
and easier to 
administer.  
Immunogenicity   Reduces cost and easier 
to administer. 
Minimal – might need 
supplementary 
information campaigns 
No experience given 
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